Combining the AstraZeneca and the Pfizer can give amazing results

Combining the AstraZeneca and the Pfizer can give amazing results

A recent study has found that mixing and matching the dose of vaccines can give better results. The study was conducted with the two most common vaccines against the coronavirus, the AstraZeneca and the Pfizer. The reason for the study was the fact that there has always been a shortage of vaccines reported after the use began. While few stocks seem to be exhausted, others might be available at that point. Several people around the globe are missing the deadline for the second dose and are running late due to the shortage of vaccines. If this shortage can be met by combining doses, the people might face lesser problems, and the pandemic might be well handled.

The story of the study:

The study was conducted in Spain. Most of the participants were randomly selectly to have a better result. The people were the ones who had already been administered with the AstraZeneca or the Oxford vaccine. After at least two months or eight weeks, they were administered with Pfizer or the BioNTech vaccine. The results were strongly favorable as the combination helped patients to develop a strong and safe immune response. The study thus proves that a combination of Pfizer and AstraZeneca can be very highly helpful against COVID infection.

The need for the study:

The vaccine crisis has always been the reason behind the study, but a few other reasons also add to its necessity. There have been blood clots reported after the vaccination done with AstraZeneca. Though the number of such cases is more minor, few countries have been worried about giving people a second dose of the same. Few countries like the US, France, and Germany have already approved the vaccine combination, taking the situation seriously. This study also helps other countries understand that there is no harm in combining and mixing the doses. This would also help in speeding up the vaccine drive.

About Camelia Bhattacharyya 83 Articles
Camelia is an intern for PanAsiaBiz studying at the Amity University, Kolkata [B. Tech (biotechnology)]. She is fond of writing on Science, Health, and Biotechnology topics.

Be the first to comment

Leave a Reply

Your email address will not be published.


*